Product Reports Resources Pricing Login Book a demo

Synnovation Therapeutics

Biotech & Life Sciences · Philadelphia, United States · Founded 2021

Synnovation Therapeutics is a precision medicine company that focuses on developing small molecule therapies to treat cancer. These therapies are designed to be highly effective against specific disease targets, which have been thoroughly validated through scientific research. The company leverages its deep expertise in cancer biology and a top-tier medicinal chemistry team to create a diverse range of targeted therapies. Synnovation Therapeutics operates in the biotechnology and pharmaceutical market, specifically within the oncology (cancer treatment) sector. The company primarily serves patients suffering from various forms of cancer, aiming to improve their lives through innovative treatments. The business model of Synnovation Therapeutics revolves around the discovery and development of new drugs. They invest heavily in research and development (R&D) to create these small molecule therapies. Once a promising therapy is developed, the company advances it into clinical trials, a crucial step in bringing a new drug to market. Synnovation Therapeutics makes money by developing these therapies and then either selling them directly, licensing them to larger pharmaceutical companies, or partnering with other organizations to bring the drugs to market. This model allows them to generate revenue while continuing to invest in new research and development projects. In summary, Synnovation Therapeutics is dedicated to transforming cancer care through patient-focused precision medicine. They are committed to building a skilled and passionate team to drive their mission forward, emphasizing teamwork and diversity within their company culture. Keywords: precision medicine, small molecule therapies, cancer treatment, oncology, drug discovery, clinical trials, biotechnology, pharmaceutical, targeted therapies, R&D investment.

Investors

5 investors on Synnovation Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Third Rock Ventures
Nextech Invest
Cormorant Asset Management
Lilly Asia Ventures
Sirona Capital

Global footprint

Where Synnovation Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States97.4%
🇨🇭 Switzerland2.6%
2 countries shown

Talent graph

The shape of Synnovation Therapeutics's talent

Dealroom maps Synnovation Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

4 team members profilednamed & role-tagged by Dealroom
51 employeestotal headcount
1 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Synnovation Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Synnovation Therapeutics

An AI-synthesized read of the highest-engagement posts about Synnovation Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synnovation Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.